EU states back spending up to $2.7 billion upfront on COVID-19 vaccines

EU states back spending up to $2.7 billion upfront on COVID-19 vaccines
A Schott AG employee handles a borosilicate glass tubing, the material which will be used in vials or syringes to hold the eventual coronavirus disease (COVID-19) vaccine, during one of the stages of production at an undisclosed location in this 2014 handout image courtesy of Schott AG. (SCchott AG/Handout via Reuters)
Short Url
Updated 13 June 2020

EU states back spending up to $2.7 billion upfront on COVID-19 vaccines

EU states back spending up to $2.7 billion upfront on COVID-19 vaccines

BRUSSELS: The European Commission received a mandate from EU governments on Friday to negotiate advance purchases of promising coronavirus vaccines, the EU’s top health official said, but it is unclear whether there is enough money available.

The bloc is scrambling to sign advance deals with pharmaceutical companies to secure coronavirus vaccines under development, fearing a successful shot might not be available for Europeans soon enough. EU health ministers gave “overwhelming” backing for a Commission plan to use an emergency fund of currently €2.4 billion ($2.7 billion) to buy coronavirus vaccines upfront, Health Commissioner Stella Kyriakides told journalists after a videoconference with representatives of the 27 EU governments.

Under the plan, the EU would use most of the money available in that fund to buy in advance up to six vaccines for its 450 million people, EU officials said. Such a multiple vaccine strategy could cost much more than the $1.2 billion deal signed by the US in May to secure 300 million doses of a single coronavirus vaccine being developed by British drugmaker AstraZeneca.

Asked whether EU states should provide extra funds, Kyriakides said there was no need for further financial commitments at the moment. An EU official said member states’ financial support was welcome.

The EU is planning a vaccination strategy that would target the most vulnerable, which would reduce the number of doses immediately needed, and the upfront payments. But it is unclear whether governments support the plan.

Under the advance purchasing plans, the EU would buy or commit to buying promising vaccines before they are ready, taking the risk of potential clinical failures. In exchange, it would get priority access to the shots.

The bloc has accepted extra risks so as not to lag behind China and the US in the race to a vaccinet.

The commissioner said that the EU executive had already discussed its plans with pharmaceutical companies, but declined to name them. She also did not answer questions about the timing  of the possible advance purchasing deals.

AstraZeneca, France’s Sanofi, and US players Pfizer, Novavax, Johnson & Johnson and Moderna are among companies trialling vaccines.

EU officials said the bloc would not buy vaccines produced exclusively in the US, fearing that would delay supplies to Europe.

With backing secured for the Commission, it remains unclear whether the wealthiest EU states will continue to pursue parallel talks with drugmakers.

Germany, France, Italy and the Netherlands are already in talks with pharmaceutical companies to buy vaccines, a move that could weaken the EU’s joint approach.

Kyriakides said the two initiatives had the same goal. But she added: “Both tracks should converge for the benefits of all 27. This is about working together and not in competition.”